Phase 2Recruiting
Mindfulness-based Psilocybin Therapy for PTSD
A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)
- Sponsor
- Anthony P King (Academic or other)
- Enrollment
- 30 planned
- Conditions
- Post Traumatic Stress Disorder; Depression - Major Depressive Disorder
- Interventions
- Psilocybin + MBCT therapy; Active Comparator: Psilocybin with Support Only
- Ages
- adults, older adults
- Registry
- NCT07104916
Full record on ClinicalTrials.gov
From the registry
The goal of this study is to learn how psilocybin delivered with mindfulness-based therapy may help symptoms of posttraumatic stress disorder (PTSD). This is an assessor-blinded, randomized, controlled study in participants with PTSD. The study will investigate the changes in brain activity, connectivity, and microstructural neuroplasticity assessed using EEG/EMG and multimodal MRI measures after administration of one oral dose of psilocybin, accompanied either with standard "psychological support" only; or with standard support plus Mindfulness-based Cognitive Therapy (MBCT).
Primary outcomes
- Changes in parameter estimate of regional brain activity measured by fMRI after one dose of psilocybin in participants with PTSD
- Changes in region-to-region connectivity measured by fMRI after PAT with one dose of psilocybin in patients with PTSD
- Changes in event related potentials (ERP) after PAT with one dose of psilocybin in participants with PTSD
- Changes in acoustic startle electromyographic (EMG) response after PAT with one dose of psilocybin in patients with PTSD
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered